Skye Bioscience, Inc. Financing Receivable, after Allowance for Credit Loss, Current
Skye Bioscience, Inc. (SKYE) had Financing Receivable, after Allowance for Credit Loss, Current of $12.83 thousand as of 2014-07-31, per its 10-Q filed 2014-09-15.
Discontinued › Balance Sheet › Assets › Assets, Current › Accounts and Financing Receivable, after Allowance for Credit Loss, Current
us-gaap:NotesAndLoansReceivableNetCurrent · last filed 2014-09-15
- 2014-07-31: Financing Receivable, after Allowance for Credit Loss, Current $12.83K.
- 2014-04-30: Financing Receivable, after Allowance for Credit Loss, Current $2.54K.
- 2014-01-31: Financing Receivable, after Allowance for Credit Loss, Current $8.39K.
- 2013-10-31: Financing Receivable, after Allowance for Credit Loss, Current $13.02K.
| Period end | Financing Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2014-07-31 | $12.83K 10-Q · filed 2014-09-15 |
| 2014-04-30 | $2.54K 10-Q · filed 2014-06-05 |
| 2014-01-31 | $8.39K 10-Q · filed 2014-03-17 |
| 2013-10-31 | $13.02K 10-Q · filed 2014-09-15 |
| 2013-07-31 | $17.43K 10-Q · filed 2013-09-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |